Skip to content

Comparison of Two Laser Therapy Methods for PDR

Comparison Between Result and Side Effects of Treatment of Prolifrative Diabetic Retinopaty by Conventional and Extended Targeted Pan Retinal Photocoagolation

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01232179
Acronym
PDR
Enrollment
Unknown
Registered
2010-11-02
Start date
2010-10-31
Completion date
2011-05-31
Last updated
2010-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proiriftrative Diabetic Retinopathy

Brief summary

Proliferative diabetic retinopathy (PDR) is treated with conventional pan retinal photocoagulation (PRP) which can improve the visual prognosis in this complication significantly. However , the treatment may also resulting adverse effects such as blurring of central vision, visual field constriction and disturbance in dark adaptation and contrast vision. Extended targeted retinal coagulation (TRP) to the ischemic areas may cause regression of the neovascularization while minimizing some of the risks and complication associated of treatment of PDR with these two methods.

Interventions

PROCEDUREconventional prp

pan retinal photocoagulation

PROCEDUREtargeted prp

1200-1600 spot in far periphery retin, anterior equator

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients with PDR condidate for photocoagulation teraphy * Pupil with dilatasion≥6mm * without privious treatment with anti VEGF drugs 3months before study * without privious vitroretinal sugery * without privoius lasertraphy

Exclusion criteria

* To have NVI cricteria with increase of inraocular pressure * to have cataract or vitrus leakage which prevent lasertraphy * pupil smaller that 6mm * traditional retinal detachment * privious treatment with anti VEGF drugs 3months before study * privious PRP * patient unable to get wide field FAG

Design outcomes

Primary

MeasureTime frame
no leakage in widefield fluorescin angiography3 months after lasertraphy

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026